These benefits, along with a previous report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like behavior in mice,2 aid the concept of targeting ACKR3 as a unique strategy to modulate the opioid process, which could open new therapeutic avenues for opioid-relevant Diseases. These success propose that conolidine is https://carlosf177lbs3.blognody.com/profile